Table 1.

Clinical characteristics of patients included in this study

Doxorubicin (51)FUMI (30)
Response
    PD87
    SD2213
    PR2110
Histology
    Ductal4626
    Other54
TP53 mutations2416
Median age62 (32–85)64 (37–82)
Median OS (mo)33 (7–92)24 (3–54)
No. relapses2617
  • Abbreviations: PD, progressive disease; SD, stable disease; PR, partial response; OS, overall survival.